Impower010 trial update confirms adjuvant atezolizumab efficacy for patients with high PD-L1 expression

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Mar 31 / Springer Healthcare

Impower010 trial update confirms adjuvant atezolizumab efficacy for patients with high PD-L1 expression

Oncology Lung Cancer ELCC-2022

Description

Nasser Altorki talks through the high PD-L1 expression sub-analysis findings from the IMpower010 trial of adjuvant atezolizumab versus best supportive care for stage II–IIIA NSCLC.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.